WATERTOWN, Mass. — January 8, 2026 — Leads & Copy — Acrivon Therapeutics, Inc. (Nasdaq: ACRV) announced progress across its pipeline, including updates on the Phase 2 ACR-368 program, initial clinical data from the ACR-2316 Phase 1 study, and the nomination of ACR-6840, a potential first-in-class, oral CDK11 inhibitor.
According to the company, electronic data capture (EDC) from the ongoing ACR-368 Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed a 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy. Data from all-comer subjects with serous subtype and ≤2 prior lines of therapy showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM levels across serous subjects.
The company has submitted a Phase 3 confirmatory protocol to the FDA for ACR-368 plus anti-PD-1 therapy in frontline EC subjects, based on preclinical AP3 data showing synergy between ACR-368 and anti-PD-L1. Global trial readiness is expected mid-2026. Arm 3 is enrolling up to 90 subjects with serous subtype and ≤2 prior lines of therapy, without requirement for a tumor biopsy, for treatment with ACR-368 plus ultra-low dose gemcitabine (ULDG) as a tumor sensitizer. Enrollment completion is expected in the fourth quarter of 2026.
Initial data from Phase 1 dose escalation (N=33) for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, showed favorable tolerability. Two weekly oral dosing regimens (160 mg QD, 3d on/4d off and 240 mg QD, 2d on/5d off) were established with a bi-weekly regimen initiated. Tumor shrinkage was observed at ≥120 mg dose level in 9/20 subjects, including a confirmed PR in EC, and unconfirmed PRs in SCLC and sqNSCLC. ACR-6840, a potential first-in-class AP3-derived oral CDK11 inhibitor, has been nominated as the next preclinical development candidate, with IND submission planned for the fourth quarter of 2026.
Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and co-founder of Acrivon, stated that the company is pleased with progress across multiple high-value opportunities and is particularly excited by the observation from the ACR-368 Phase 2 trial that subjects with serous endometrial cancer with up to two prior lines of therapy are showing over 50% confirmed response rate.
Mansoor Raza Mirza, M.D., chief medical officer of Acrivon, noted that incorporating feedback from a Type B meeting in June 2025, the company recently submitted its Phase 3 confirmatory study protocol to the FDA for ACR-368 in combination with anti-PD-1 therapy in frontline endometrial cancer patients.
The company expects to initiate enrollment for Arm 3 of the ACR-368 Phase 2 trial in the EU in Q1 2026, provide an additional update on Arm 1 and initial clinical data from Arm 3 of the ACR-368 Phase 2 trial in mid-2026, and achieve readiness for the Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy in mid-2026. It also expects to complete enrollment in the Phase 2 Arm 3 trial for ACR-368 combined with ULDG as a sensitizer in Q4 2026, report additional ACR-2316 Phase 1 clinical data in weekly and bi-weekly dosing regimens and transition into dose expansion in select tumor types in 1H 2026, submit an IND to the FDA for ACR-6840 in Q4 2026, and initiate additional internal programs utilizing the AP3 platform in 2H 2026.
As of December 31, 2025, the company had preliminary, unaudited cash, cash equivalents, and investments of approximately $119 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027.
The company held an investor conference call and webcast today at 8:30 a.m. ET.
Contact:
Adam D. Levy, Ph.D., M.B.A.
alevy@acrivon.com
Alexandra Santos
asantos@wheelhouselsa.com
Source: Acrivon Therapeutics, Inc.